These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26751211)

  • 1. Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.
    Singh S; Vedi S; Samrat SK; Li W; Kumar R; Agrawal B
    PLoS One; 2016; 11(1):e0146404. PubMed ID: 26751211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens.
    Agrawal B; Gupta N; Vedi S; Singh S; Li W; Garg S; Li J; Kumar R
    Cells; 2019 May; 8(5):. PubMed ID: 31130710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
    Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.
    Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; Borrás-Cuesta F; Paranhos-Baccala G; Prieto J; Ruiz J; Lasarte JJ
    Vaccine; 2002 Dec; 21(3-4):202-10. PubMed ID: 12450695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
    Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
    J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
    Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
    Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus.
    Makimura M; Miyake S; Akino N; Takamori K; Matsuura Y; Miyamura T; Saito I
    Vaccine; 1996 Jan; 14(1):28-36. PubMed ID: 8821646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
    Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
    J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.
    Zabaleta A; Llopiz D; Arribillaga L; Silva L; Riezu-Boj JI; Lasarte JJ; Borrás-Cuesta F; Prieto J; Sarobe P
    Mol Ther; 2008 Jan; 16(1):210-7. PubMed ID: 17923840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
    Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
    Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques.
    Wen B; Deng Y; Chen H; Guan J; Chuai X; Ruan L; Kong W; Tan W
    Mol Ther; 2013 Sep; 21(9):1787-95. PubMed ID: 23774793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice.
    Pancholi P; Perkus M; Tricoche N; Liu Q; Prince AM
    J Virol; 2003 Jan; 77(1):382-90. PubMed ID: 12477843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
    PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
    Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
    Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
    J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.